Ozempic has ‘very rare’ sight loss side effect, EU drugs regulator finds
The EMA’s drug safety committee launched a review of medicines containing semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus — in January.
You are not logged in so some information on this page has been withheld. To see more, please log in.
EMA
since
auto-detected in 34 stories
27 hours ago
4 months ago
Struggling students to benefit from grant changes
The household income threshold for EMA will rise after a 15-year freeze, the Welsh government says.
page 1 of 1